Zhejiang Peptites Biotech is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 7 molecules. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 8 September 2023 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3015685285 |
| Molecule | Regulators | Docs |
|---|---|---|
| Semaglutide | US FDA | 4 |
| Tirzepatide | US FDA | 2 |
| Etelcalcetide | US FDA | 1 |
| Leuprolide | US FDA | 1 |
| Linaclotide | US FDA | 1 |
| Liraglutide | US FDA | 1 |
| Retatrutide | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MFDS (Korea) | None | 2 |
| US FDA | None | 1 |
Choose your molecules and target markets. Zhejiang Peptites Biotech comes back tiered against every other supplier able to file there.
Start for free